Reactivation of Unstable Angina after the Discontinuation of Heparin

New England Journal of Medicine

Volumn 327, Issue 3, 1992, Pages 141-145

  Théroux, Pierre ^a   Waters, David ^a   Lam, Jules ^a   Juneau, Martin ^a   Mccans, John ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PLACEBO;

ARTICLE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

EID: 0026736119     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199207163270301     Document Type: Article

References (30)

1. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105–11.
2. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983; 309: 396–403.
3. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75.
4. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225–8.
5. Neri Semeri GG, Gensini GF, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 1990; 335: 615–8.
6. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565–74.
7. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109–14.
8. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320: 352–7.
9. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855–8.
10. Lagerstedt CI, Olsson C-G, Fagher BO, Öqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515–8.
11. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 581–9.
12. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 1983; 78: 427–34.
13. Engelman L, Hartigan JA. K-means clustering of cases. In: Dixon WJ, ed. BMDP statistical software. Berkeley: University of California Press, 1988: 831–42.
14. Halverstadt DB, Albers DD, Kroovand RL, Rich R. Anticoagulation in urologic surgery. Urology 1977; 6: 617–9.
15. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30.
16. Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220–30.
17. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213–20.
18. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219–25.
19. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657–65.
20. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18–27.
21. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198–205.
22. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination by aspirin. Circulation 1976: 54: 365–70.
23. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating anti thrombin-III. Lancet 1977; 2: 581–4.
24. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency. J Clin Invest 1985; 76: 826–36.
25. von Kaulla E, von Kaulla KN. Deficiency of antithrombin III activity associated with hereditary thrombosis tendency. J Med (Basel) 1972; 3: 349–58.
26. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparin sulfate and dermatan sulfate. Thromb Res 1976; 8: 859–67.
27. Hirsh J. Laboratory diagnosis of thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: J.B. Lippincott, 1987:1173–4.
28. Mombelli G, Im Hof IV, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684–9.
29. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
30. Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches. Biomed Biochim Acta 1985; 44: 1007–13.